 Posted: Wed 21:37, 23 Mar 2011 Post subject: Low molecular weight heparin in the treatment of a |
|
| Low molecular weight heparin in the treatment of acute cerebral infarction term clinical observation
Treatment, patients are abdominal pain, vomiting, nausea, watery solution,tory burch shoes, fever with dizziness, Received Date: 2003.06. I5 Author: Liu Enlan (I965.), female, Ji'an County, inspection technician fatigue, without tenesmus and stool pus and blood. After rehydration and other anti-inflammatory treatment,mbt chaussures paris, all cured. The remaining 21 were mild symptoms, the out-patient treatment, are unharmed. 3 laboratory 3. I test material 3. I. I sample from (I) in patients with eating stewed chicken wings, chicken feet 5 copies. (2) the owner at the brine chicken wings, chicken feet, braised pork skin of I copies of frozen chicken wings, chicken feet were all I. (3) patients vomit 8 copies of 43 anal swabs. 3. I. 2 Experimental Materials (I) MM enrichment broth enrichment broth (self-made) 7.5% NaC1 broth. (2) WS selective differential isolation medium agar; ss agar; yolk agar Ba a Parker medium manufacturers for inspection by Zhejiang epidemic Military Logistics. (3) have the same biochemical literature reports Kam l. That the use of conventional doses of LMWH does not increase the incidence of secondary intracranial hemorrhage. In addition to the other 3 cases local injection site ecchymosis, but did not find the other heparin-related side effects, even without treatment because of side effects of withdrawal. Subcutaneous LMWH easily absorbed,tory burch reva, bioavailability Because of its safety, tolerability, convenience, LMWH has been used for other indications such as deep vein thrombosis (DVT) in patients treated outside the hospital. Patients suffering from cerebral infarction at a significant hypercoagulable state, anticoagulation therapy can improve the hypercoagulable state. Early anticoagulant therapy also can significantly improve the collateral circulation, to prevent the Kay, etc. for 306 patients were randomized double-blind multi-center clinical trials, the incidence within 24h as with LMWH, and were followed for 6 months, suggesting that may improve the prognosis and quality of life, reduce morbidity or mortality t. This LMWH treatment group, in terms of neurological function or clinical effective rate than the control group, in which the basic recovery rate of 375%,tory burch outlet, better efficacy. Although the United States Institute of Neurology and Stroke (NINDS) has affirmed and recommended thrombolytic therapy for acute cerebral infarction. ... Accordingly the first FDA approval of thrombolytic agents in the t-DA and the n-pA can be used in acute cerebral infarction, but need to take 7.4% higher than the non-thrombolytic therapy in 84 * the risk of secondary intracranial hemorrhage, 59 % of symptomatic intracranial hemorrhage. Thrombolytic therapeutic window for the 3-6h .... There are other candidates for the same time the strict criteria and contraindications and the need for excellent care facilities,belstaff outlet, the treatment of acute cerebral infarction thrombolytic therapy often have lost the opportunity or can not tolerate this treatment. LMWH therapy may be used at this time, is safe and effective, and treatment costs far less than thrombolytic therapy. |
|
